Enzo Biochem has announced the New York State Department of Health has approved Enzo Clinical Labs' use of the company's ColonSentry test, according to a news release.
The test uses RNA contained in blood to measure the level of the expression of seven genes and provide an assessment of a patient's risk of having colorectal cancer.
The test, which requires a small sample of blood, was originally developed by GeneNews.
Related Articles on Colorectal Cancer Prevention:
Ohio Gastroenterology Group Provides Free Colonoscopies to Uninsured
American College of Physicians Issues New Guidance for Colorectal Cancer Screening
Kentucky's Tri-State Gastroenterology Associates to Provide Free Colon Cancer Education Program